You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Details for Patent: 10,603,282


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,603,282
Title:Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
Inventor(s): Panmai; Santipharp (Cranford, NJ), Tatavarti; Aditya (Chalfont, PA), Farrington; Andrew M. (Collegeville, PA), Biyyala; Varsha (Somerset, NJ), Allain; Leonardo R. (Lansdale, PA), Nefliu; Marcela (Schwenksville, PA), Klinzing; Gerard R. (Wilmington, DE), Ren; Jie (Chalfont, PA), Lamm; Matthew (Morristown, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:15/780,142
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,603,282: A Comprehensive Analysis

Introduction

United States Patent 10,603,282, issued on March 31, 2020, is a significant patent in the pharmaceutical sector, particularly in the treatment of HIV infection. This patent, assigned to Merck Sharp & Dohme Corp., details pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate, and lamivudine.

Inventors and Assignees

The patent was invented by a team of researchers including Panmai Santipharp, Tatavarti Aditya, Farrington Andrew M., Biyyala Varsha, Allain Leonardo R., Nefliu Marcela, Klinzing Gerard R., Ren Jie, and Lamm Matthew. The assignee of this patent is Merck Sharp & Dohme Corp., a major pharmaceutical company[2].

Scope of the Patent

The patent pertains to pharmaceutical compositions that combine doravirine, tenofovir disoproxil fumarate, and lamivudine. These compositions are specifically designed for the treatment of HIV infection. Here’s a breakdown of the key components:

  • Doravirine: A non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV.
  • Tenofovir Disoproxil Fumarate: A nucleotide reverse transcriptase inhibitor (NtRTI) that also inhibits HIV replication.
  • Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) that is effective against HIV and hepatitis B[2].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

  • Composition Claims: The patent claims pharmaceutical compositions that contain specific amounts of doravirine, tenofovir disoproxil fumarate, and lamivudine. These compositions can be in various forms such as tablets, capsules, or other solid dosage forms[1][2].
  • Process Claims: The patent also claims processes for making these pharmaceutical compositions, including methods for formulating, manufacturing, and testing the final products[1][2].

Formulation Ingredients

The compositions may include additional formulation ingredients to enhance their stability, bioavailability, and patient compliance. These ingredients can include:

  • Diluents: Substances that increase the bulk of the formulation.
  • Binders: Substances that hold the formulation together.
  • Compression Aids: Substances that help in the compression of the formulation into tablets.
  • Disintegrants: Substances that help the tablet disintegrate in the body.
  • Lubricants: Substances that reduce friction during the manufacturing process.
  • Glidants: Substances that improve the flow of the powder during manufacturing. Colloidal silica is specifically mentioned as a glidant in this class of the invention[1].

Patent Expiration Dates

The patent is set to expire on November 29, 2036. This expiration date is crucial for understanding the timeline during which Merck Sharp & Dohme Corp. holds exclusive rights to these pharmaceutical compositions[2].

Exclusivity Periods

In addition to the patent expiration, the FDA has granted exclusivity periods that can run concurrently with the patent. For this particular drug, the exclusivity period is set to expire on January 27, 2025, for new patient populations[2].

Related Patents and Exclusivities

There are related patents and exclusivities that complement this patent. For example, Patent 10,842,751, also issued to Merck Sharp & Dohme Corp., covers similar pharmaceutical compositions and processes. These related patents and exclusivities help in maintaining a comprehensive intellectual property portfolio for the treatment of HIV infection[2].

Market Impact

The absence of a generic version of Delstrigo, the brand name for the combination of doravirine, tenofovir disoproxil fumarate, and lamivudine, means that Merck Sharp & Dohme Corp. retains a significant market advantage until the patent and exclusivity periods expire. This is particularly important in the HIV treatment market, where brand loyalty and patent protection can significantly influence market share[2].

Conclusion and Key Takeaways

  • Patent Scope: The patent covers specific pharmaceutical compositions and processes for treating HIV infection.
  • Key Components: Doravirine, tenofovir disoproxil fumarate, and lamivudine.
  • Formulation Ingredients: Include diluents, binders, compression aids, disintegrants, lubricants, and glidants.
  • Patent Expiration: November 29, 2036.
  • Exclusivity Periods: January 27, 2025, for new patient populations.
  • Market Impact: Significant market advantage for Merck Sharp & Dohme Corp. until patent and exclusivity periods expire.

FAQs

  1. What are the main components of the pharmaceutical compositions covered by US Patent 10,603,282?

    • The main components are doravirine, tenofovir disoproxil fumarate, and lamivudine.
  2. Who is the assignee of this patent?

    • The assignee is Merck Sharp & Dohme Corp.
  3. What is the purpose of the pharmaceutical compositions described in this patent?

    • The compositions are designed for the treatment of HIV infection.
  4. When is the patent set to expire?

    • The patent is set to expire on November 29, 2036.
  5. Is there a generic version of Delstrigo available in the United States?

    • No, there is currently no therapeutically equivalent generic version of Delstrigo available in the United States[2].

Cited Sources:

  1. US10603282B2 - Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine - Google Patents
  2. Generic Delstrigo Availability - Drugs.com
  3. Patent Landscape Reports by Other Organizations - WIPO
  4. Pharmaceutical compositions containing doravirine, tenofovir ... - PubChem
  5. US-10842751-B2 - Unified Patents Portal

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,603,282

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Merck Co DELSTRIGO doravirine; lamivudine; tenofovir disoproxil fumarate TABLET;ORAL 210807-001 Aug 30, 2018 RX Yes Yes 10,603,282 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,603,282

PCT Information
PCT FiledNovember 29, 2016PCT Application Number:PCT/US2016/063894
PCT Publication Date:June 08, 2017PCT Publication Number: WO2017/095761

International Family Members for US Patent 10,603,282

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016361612 ⤷  Try for Free
Brazil 112018011085 ⤷  Try for Free
Canada 3006192 ⤷  Try for Free
China 108367008 ⤷  Try for Free
Cyprus 1124748 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.